- The Economic Times
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Metrics to compare | BION | Peers Peers - average of corresponding metrics from companies closely matching BION: PANACEABIO, MOREPENLAB, LUPIN, 688177, ABBOTINDIA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIONPeersSector |
---|---|---|---|---|
P/E Ratio | 29.3x | 35.7x | −0.6x | |
PEG Ratio | 0.10 | 0.32 | 0.00 | |
Price/Book | 2.3x | 5.9x | 2.6x | |
Price / LTM Sales | 3.1x | 4.9x | 3.1x | |
Upside (Analyst Target) | −11.3% | 1.3% | 56.2% | |
Fair Value Upside | Unlock | −19.3% | 7.7% | Unlock |